TLRY - Public offerings

Reported Net Revenue at $153.2 Million; On a Constant Currency Basis, Net Revenue Remained Strong at $166.5 Million Cannabis Gross Margin Increased to 51% from 43% in the Prior Year Quarter Delivered $108 Million in Annualized Cash Savings to Date, Expects to Deliver $130 Million Across Corporate Optimization Plans Second Highest Adjusted EBITDA in Company's History Marking the 14th Consecutive Quarter of Positive Adjusted EBITDA Strong Balance Sheet with ~$500 Million in Cash Company Reconfirms Guidance to Generate $70-$80 Million of Adjusted EBITDA and be Free-Cash Flow Positive in Its Operating Business Units this Fiscal Year Tilray Brands Maintains #1 Cannabis Market Share in Cana

Alliance Looks to Enhance Consumer Experience and Strengthen Tilray Brands' Potential for U.S. Federal Legalization and International Expansion Transaction Expected to Immediately be Revenue, EBITDA and Cash-Flow Positive, and Accretive to EPS for Tilray Brands LEAMINGTON, Ontario, July 12, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray Brands" or the "Company") ((Nasdaq, TSX:TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that the Company has closed its previously-disclosed acquisition from HT Investments MA LLC ("HTI") of the secured convertible note (the

Jake Cohen appointed as CEO Eula Adams, MBA, CPA appointed as Interim CFO and a nominated Board Member Chris Lund appointed as Chief Commercial officer Corporate rebrand initiated Operations enhancements internalizing finance, administration and marketing Appointment of new board members VANCOUVER, BC, Oct. 12, 2021 /PRNewswire/ - Hollister Biosciences Inc. (CSE:HOLL) (OTC:HSTRF) (FRANKFURT: HOB) (the "Company", "Hollister Cannabis Co." or "Hollister") is pleased to announce a series of operational and strategic updates to create shareholder value, enhance; governance, operations and market positioning while preparing the Company for the next phase of its growth. Background In November

Calgary, Alberta--(Newsfile Corp. - May 26, 2021) - High Tide Inc. (TSXV:HITI) (OTCQB:HITID) (FSE: 2LYA) ("High Tide" or the "Company") a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, is pleased to announce the closing of its previously announced "bought deal" offering (the "Offering") of units of the Company (the "Units"), including the exercise in full of the underwriters' over-allotment option. The Offering was led by ATB Capital Markets Inc. and Echelon Wealth Partners Inc., together with Beacon Securities Limited, Desjardins Securities Inc. and Roth Canada, ULC (collectively, the "Underwriters"), and A.G.P./Alliance Global

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ CALGARY, AB, May 19, 2021 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (TSXV:HITI) (OTCQB:HITIF) (FRA:2LY), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, is pleased to announce today that it has entered into an amended agreement with ATB Capital Markets Inc. ("ATB") and Echelon Wealth Partners Inc. ("Echelon"), on behalf of a syndicate of underwriters (together, the "Underwriters"), to increase the size of the previously announced bought deal

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ CALGARY, AB, May 18, 2021 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (TSXV:HITI) (OTCQB:HITIF) (FRA: 2LY), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, is pleased to announce today that it has entered into an agreement with ATB Capital Markets Inc. ("ATB") and Echelon Wealth Partners Inc. ("Echelon"), on behalf of a syndicate of underwriters (together, the "Underwriters").

LONDON, Dec. 4, 2020 /PRNewswire/ -- Depression is now the number one disability in the world. And it's costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twice recently called a "breakthrough therapy" is shaping up to be the revolutionary treatment that big pharma has been waiting for. And it's being backed by what Forbes describes as Silicon Valley legends, billionaire financiers and patent attorneys.   Mentioned in today's commentary includes:  Aurora Cannabis Inc. (NYSE: ACB), Canopy Growth Corporation (NASDAQ: CGC), Tilray, Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON), Aphria Inc. (NASDAQ: APHA). Right on the